{"nctId":"NCT00369278","briefTitle":"Intensified vs. Standard Dose Therapy With Mycophenolate Sodium Plus Cyclosporin Microemulsion and Corticosteroid Combination in Patients With de Novo Renal Transplant Patients","startDateStruct":{"date":"2006-06"},"conditions":["Renal Transplantation"],"count":128,"armGroups":[{"label":"Intensified Mycophenolate sodium","type":"EXPERIMENTAL","interventionNames":["Drug: Enteric-coated mycophenolate sodium (EC-MPS)"]},{"label":"Standard Mycophenolate sodium","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Enteric-coated mycophenolate sodium (EC-MPS)"]}],"interventions":[{"name":"Enteric-coated mycophenolate sodium (EC-MPS)","otherNames":["myfortic"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria\n\n1. Recipients of de novo cadaveric, living unrelated or living related kidney transplants\n2. Females capable of becoming pregnant must have a negative serum pregnancy test within 7 days prior to or at baseline, and are required to practice an approved method of birth control for the duration of the study and for a period of 6 weeks following discontinuation of study medication, even where there has been a history of infertility.\n3. Patients who are willing and able to participate in the study and from whom written informed consent has been obtained.\n\nExclusion criteria\n\n1. More than one previous renal transplantation\n2. Graft loss due to immunological reasons in the first year after transplantation (in case of secondary transplantation)\n3. Multi-organ recipients (e.g., kidney and pancreas) or previous transplant with any other organ, different from kidney\n4. Patients receiving a kidney from a non-heart beating donor\n5. Patients who are recipients of A-B-O incompatible transplants\n\nOther protocol-defined inclusion/exclusion criteria may apply","sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Time to First Occurrence of a Mycophenolic Acid (MPA) Plasma Concentration of â‰¥ 40 mg*h/L","description":"Non-compartmental MPA pharmacokinetic parameters were derived from individual plasma concentration-time profiles using WinNonLin 5.2 software. The areas under the curve were calculated by means of the linear trapezoidal rule.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.00","spread":null},{"groupId":"OG001","value":"43.00","spread":null}]}]}]},{"type":"PRIMARY","title":"Time to First Occurrence of Any Treatment Failure During the First 6 Months Post-treatment or at Month 6 Post-treatment","description":"Median time to first occurrence of treatment failure was not reached in this study.","classes":[]},{"type":"SECONDARY","title":"Number of Participants With Single Treatment Failures","description":"Rates for all individual components of the primary endpoint 'treatment failure' until day 180:\n\n* Acute rejection diagnosed by biopsy (BPAR)\n* graft loss\n* death\n* loss to follow up\n* discontinuation from study drug due to lack of efficacy or toxicity (adverse events, every adverse event had to be interpreted as toxicity)\n* conversion to another dosing regimen (conversion to tacrolimus, prograf, etc.)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"24","spread":null}]}]}]},{"type":"SECONDARY","title":"Rates of Events for Treated Acute Rejection, Death, Graft Loss, or Loss to Follow up on Day 28, Day 84, and Day 180","description":"Due to a small number of events, median time to \\<event\\> was not reached.","classes":[]},{"type":"SECONDARY","title":"Time to \"Event\" for the Composite Endpoint as Well as All Individual Components of That Endpoint \"Treatment Failure\" Including Clinical Rejections","description":"Due to a small number of events, median time to \\<event\\> was not reached.","classes":[]},{"type":"SECONDARY","title":"Renal Function as Measured by Serum Creatinine","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.0","spread":"2.7"},{"groupId":"OG001","value":"7.8","spread":"2.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":"1.5"},{"groupId":"OG001","value":"2.6","spread":"2.2"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Any Treatment Failure","description":"Treatment failures were defined as a composite endpoint of biopsy proven acute rejection (BPAR), graft loss, and death, loss to follow up and discontinuations from study drug treatment due to lack of efficacy or toxicity (at least one condition must be present) during the first 6 months or until final assessment. Any participants who were suspected of having acute rejection episodes had biopsies performed to prove whether a rejection had occurred. Graft loss was considered as the day the patient started dialysis and was not able to subsequently be removed or the day of graft nephrectomy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"24","spread":null}]}]}]},{"type":"SECONDARY","title":"Renal Function as Measured by Glomerular Filtration Rate (GFR)","description":"The Glomerular Filtration Rate (GFR) was calculated using the following formulas:\n\n* Cockcroft-Gault formula: calculation using the participant's age, gender, weight, and serum creatinine levels.\n* MDRD formula: calculation using the participant's age, gender, serum creatinine, urea nitrogen, and albumin levels.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.0","spread":"3.9"},{"groupId":"OG001","value":"9.4","spread":"3.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41.1","spread":"17.1"},{"groupId":"OG001","value":"40.6","spread":"24.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.1","spread":"4.8"},{"groupId":"OG001","value":"12.0","spread":"5.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.4","spread":"23.9"},{"groupId":"OG001","value":"47.9","spread":"27.1"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":44,"n":63},"commonTop":["Hypokalaemia","Urinary tract infection","Diarrhoea","Nausea","Complications of transplanted kidney"]}}}